Tag: Graham Brady

Graham Brady – 2016 Parliamentary Question to the Department for Transport

The below Parliamentary question was asked by Graham Brady on 2016-02-09.

To ask the Secretary of State for Transport, what steps he plans to take to ensure that bus service levels are maintained during the transition period before the introduction of a bus franchise.

Andrew Jones

We have given careful thought to the practical implications of the transition period and the possible safeguards that can be built in to the Bill to help maintain bus service levels for passengers. The Bill is still being drafted and it is therefore too early to confirm the detail of the process that may be proposed through the Bill.

January 1, 2023
Graham Brady – 2016 Parliamentary Question to the Department for Transport

The below Parliamentary question was asked by Graham Brady on 2016-02-09.

To ask the Secretary of State for Transport, what criteria he plans that local authorities will be expected to meet in order to justify bus franchising in their areas; and whether he plans that assessment will be subject to independent assessment.

Andrew Jones

The Buses Bill will introduce new powers for local authorities to franchise their local bus services. The Bill is still being drafted and it is therefore too early to confirm the detail of the process that may be proposed through the Bill.

January 1, 2023
Graham Brady – 2016 Parliamentary Question to the Department for Transport

The below Parliamentary question was asked by Graham Brady on 2016-02-09.

To ask the Secretary of State for Transport, what assessment his Department has made of the costs of bus franchising outside London.

Andrew Jones

The actual costs and benefits will depend on how franchising is implemented at the local level. The potential impacts of the Buses Bill proposals will be set out in the Impact Assessment which will accompany the introduction of the Bill.

When considering the costs of bus franchising it will be important for the authority to consider alternatives as well as the costs and benefits of proposals.

January 1, 2023
Graham Brady – 2016 Parliamentary Question to the Department for Transport

The below Parliamentary question was asked by Graham Brady on 2016-02-09.

To ask the Secretary of State for Transport, what discussions his Department has had with the Department for Business, Innovation and Skills on the effect of bus franchising on the vehicle manufacturing sector.

Andrew Jones

My Department has not yet entered into discussions with the Department for Business, Innovation and Skills on the effect of bus franchising on the vehicle manufacturing sector. My officials have, however, discussed proposals with the Society of Motor Manufacturers and Traders.

January 1, 2023
Graham Brady – 2016 Parliamentary Question to the Department for Transport

The below Parliamentary question was asked by Graham Brady on 2016-02-09.

To ask the Secretary of State for Transport, what steps his Department is taking to ensure that bus operators are incentivised to invest in new vehicles when franchising is an option open to local authorities after plans for the devolution of that policy are implemented.

Andrew Jones

Local transport authority with access to bus franchising powers will wish to ensure that local operators are aware of their intentions, so that investment decisions can be taken and services continue to be provided in the best interests of passengers

Any authority that chooses to implement franchising will have the ability to specify its requirements of operators as part of any franchise contract. This could include requirements relating to the standards of vehicles to be used by operators.

January 1, 2023
Graham Brady – 2016 Parliamentary Question to the Department for Energy and Climate Change

The below Parliamentary question was asked by Graham Brady on 2016-05-04.

To ask the Secretary of State for Energy and Climate Change, what information her Department holds on the viability of molten salt reactors to generate electricity.

Andrea Leadsom

In 2012, DECC published an ‘Assessment of advanced reactor systems against UK performance metrics’, which it had commissioned from the National Nuclear Laboratory. This analysis covered molten salt reactors.

These can be found online at:

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/65502/6299-assessment-reactor-systems-uk-metrics.pdf

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/65503/6302-addendum-assessment-reactor-metrics.pdf.

“

January 1, 2023
Graham Brady – 2015 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Graham Brady on 2015-12-02.

To ask the Secretary of State for Health, what the (a) target, (b) average and (c) longest time taken to approve individual funding requests are for diseases in the last 12 months for which data is available.

George Freeman

NHS England has advised that its standard operating procedures published target to process individual funding requests is 40 days. This is for all cases no matter what their outcome.

In the last 12 months for which data is available, NHS England has advised that the average approval time was 20 days, with the longest approval time being 66 days and the shortest being two days.

January 1, 2023
Graham Brady – 2015 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Graham Brady on 2015-12-02.

To ask the Secretary of State for Health, what information his Department holds on the efficacy of anakinra for patients diagnosed with idiopathic recurrent pericarditis; and what the (a) target, (b) average and (c) longest time taken to approve that drug for use was in the last 12 months for which data is available.

George Freeman

The Medicines and Healthcare products Regulatory Agency (MHRA) does not hold information concerning the efficacy of anakinra for patients diagnosed with idiopathic recurrent pericarditis.

Kineret, containing the active substance anakinra, was approved by the European Medicines Agency (EMA) in 2002 for the treatment of rheumatoid arthritis in adults. The licence was extended to include treatment of Cryopyrin-Associated Periodic Syndromes. Anakinra is not licensed to treat idiopathic recurrent pericarditis.

The EMA is required to issue an opinion on applications for new indications within 90 days of receipt of a valid application. This period will be extended if it needs to request supplementary information from the applicant. The applicant will be requested to provide supplementary information within one month, although this may be extended to two months. The assessment of any supplementary information by EMA should be completed within 60 days. The European Commission is required to amend the marketing authorisation within two months of the EMA opinion.

The MHRA does not hold information on average and longest time for approval of variations by EMA.

January 1, 2023

Graham Brady – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Graham Brady on 2015-12-17.

To ask the Secretary of State for Health, on average how many patients died in A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in the last 12 months for which data is available.

Jane Ellison

The average (mean) number of patients who died in accident and emergency (A&E) and who attended A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in 2013-14 is shown in the following table. These figures are taken from the Health and Social Care Information Centre’s Hospital Episode Statistics (HES). Final data for 2014-15 will be published on 28 January 2016.

Weekday	Average (mean) deaths in A&E department	Average (mean) attendances at A&E
Monday	59.3	55,212.7
Tuesday	54.0	49,660.8
Wednesday	56.0	48,667.0
Thursday	53.7	48,600.3
Friday	55.6	47,932.3
Saturday	55.8	48,614.6
Sunday	57.1	50,202.9

Source: (HES), Health and Social Care Information Centre

Notes:

1. The table shows the mean of A&E attendances, and the mean of A&E attendances where the patient died in the department, by weekday for 2013-14. The HES A&E database is recorded at attendance level, not patient level.

2. The data cannot be described as an average number of people as the same person may have had more than one A&E attendance within the time period presented.

3. The data excludes planned follow-up attendances.

January 1, 2023